uniQure secures FDA Accelerated Approval pathway for AMT-130; 2024 net loss $239.6M

uniQure N.V.

2024-FY EPS reported -$4.92 revenue$27,119,000

FDA agreed data from Phase I/II AMT-130 studies vs external control may support BLA; cUHDRS as intermediate endpoint, NfL as supportive.
Cash and equivalents $367.5M at Dec 31, 2024; plus $80.7M net from public offering, funds operations into H2 2027.
Net loss $239.6M ($4.92 loss per share) for 2024, vs $308.5M loss in 2023; revenues $27.1M up from $15.8M.
Completed enrollment in third cohort of AMT-130 Phase I/II; initial safety update expected Q2 2025.
Restructuring and sale of Lexington facility reduced workforce by ~65%, cut cash burn ~$70M/year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.